Document Excerpt: Best Practices for Developing Medical Affairs Professionals: Training Oversight and Curriculum

To return to the study abstract to purchase the full study - click here

This excerpt includes research findings and metrics from document #5611 "Best Practices for Developing Medical Affairs Professionals: Training Oversight and Curriculum”.

Industries Profiled:
Pharmaceutical; Biotech; Laboratories; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Consulting; Communications; Clinical Research; Education


Companies Profiled:
Adamas Pharmaceuticals; Alcon Laboratories; Alkem; Arena Pharmaceuticals; Astellas; AstraZeneca; AveXis; Bayer; Biogen; Dendreon Pharmaceuticals LLC; Eisai; EMD Serono; Endo Pharmaceuticals; Ferring Pharmaceuticals; Fidia; Gedeon Richter ; Genentech; Heron Therapeutics; Indegene; Ipsen; IQVIA; Karyopharm Therapeutics; Mallinckrodt; MEDiSTRAVA; Merck; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; PTC Therapeutics; Inc.; Sanofi; Retrophin; Rhythm Pharmaceuticals; Sanofi Genzyme; Sunovion; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; UCB Pharma; United Therapeutics; Versant

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.